Display options
Cite
Vassilev L, Ranki T, Joensuu T, et al. Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8. Oncoimmunology. 2015;4(7):e1017702doi: 10.1080/2162402X.2015.1017702.
Vassilev, L., Ranki, T., Joensuu, T., Jäger, E., Karbach, J., Wahle, C., Partanen, K., Kairemo, K., Alanko, T., Turkki, R., Linder, N., Lundin, J., Ristimäki, A., Kankainen, M., Hemminki, A., Backman, C., Dienel, K., von Euler, M., Haavisto, E., Hakonen, T., Juhila, J., Jäderberg, M., Priha, P., Vuolanto, A., & Pesonen, S. (2015). Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8. Oncoimmunology, 4(7), e1017702. https://doi.org/10.1080/2162402X.2015.1017702
Vassilev, L, et al. "Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8." Oncoimmunology vol. 4,7 (2015): e1017702. doi: https://doi.org/10.1080/2162402X.2015.1017702
Vassilev L, Ranki T, Joensuu T, Jäger E, Karbach J, Wahle C, Partanen K, Kairemo K, Alanko T, Turkki R, Linder N, Lundin J, Ristimäki A, Kankainen M, Hemminki A, Backman C, Dienel K, von Euler M, Haavisto E, Hakonen T, Juhila J, Jäderberg M, Priha P, Vuolanto A, Pesonen S. Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8. Oncoimmunology. 2015 Apr 01;4(7):e1017702. doi: 10.1080/2162402X.2015.1017702. eCollection 2015 Jul. PMID: 26140248; PMCID: PMC4485730.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2015 Apr 01;4(7):e1017702. doi: 10.1080/2162402X.2015.1017702. eCollection 2015 Jul.

Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8.

Oncoimmunology

L Vassilev, T Ranki, T Joensuu, E Jäger, J Karbach, C Wahle, K Partanen, K Kairemo, T Alanko, R Turkki, N Linder, J Lundin, A Ristimäki, M Kankainen, A Hemminki, C Backman, K Dienel, M von Euler, E Haavisto, T Hakonen, J Juhila, M Jäderberg, P Priha, A Vuolanto, S Pesonen

Affiliations

  1. Oncos Therapeutics ; Helsinki, Finland.
  2. Docrates Cancer Center ; Helsinki, Finland.
  3. Hämatologie-Onkologie; Krankenhaus Nordwest ; Frankfurt, Germany.
  4. Institute for Molecular Medicine Finland (FIMM) ; Helsinki, Finland.
  5. Division of Pathology; HUSLAB and Haartman Institute; Helsinki University Central Hospital ; Helsinki, Finland ; Genome-Scale Biology; Research Programs Unit; University of Helsinki ; Helsinki, Finland.
  6. University of Helsinki and Helsinki University Central Hospital; Cancer Gene Therapy Group ; Helsinki, Finland.

PMID: 26140248 PMCID: PMC4485730 DOI: 10.1080/2162402X.2015.1017702

Abstract

Adenoviruses are excellent immunotherapeutic agents with a unique ability to prime and boost immune responses. Recombinant adenoviruses cause immunogenic cancer cell death and subsequent release of tumor antigens for antigen presenting cells, resulting in the priming of potent tumor-specific immunity. This effect may be further enhanced by immune-stimulating transgenes expressed by the virus. We report a case of a 38-year-old female with Stage 3 metastatic micropapillary serous carcinoma of the ovary. She was treated in a Phase I study with a granulocyte-macrophage colony stimulating factor (GMCSF)-expressing oncolytic adenovirus, Ad5/3-D24-GMCSF (ONCOS-102). The treatment resulted in progressive infiltration of CD8

Keywords: Th1 polarization; anti-tumor CD8+ T cell; anti-tumor immunity; in situ vaccine; tumor infiltrating lymphocyte; viral immunotherapy

References

  1. Nature. 2002 Jan 17;415(6869):331-5 - PubMed
  2. N Engl J Med. 2003 Jan 16;348(3):203-13 - PubMed
  3. J Cancer Res Clin Oncol. 2003 Jul;129(7):397-409 - PubMed
  4. Curr Opin Immunol. 2014 Apr;27:1-7 - PubMed
  5. Immunol Rev. 2002 Oct;188:147-54 - PubMed
  6. Nature. 2014 Nov 27;515(7528):568-71 - PubMed
  7. Nat Med. 2004 Sep;10(9):942-9 - PubMed
  8. Ann Oncol. 2005 Apr;16(4):590-6 - PubMed
  9. J Transl Med. 2012 Jan 03;10:1 - PubMed
  10. Mol Ther. 2010 Oct;18(10):1874-84 - PubMed
  11. J Transl Med. 2013 Jun 13;11:147 - PubMed
  12. Cancer Immunol Immunother. 2007 May;56(5):641-8 - PubMed
  13. PLoS One. 2014 Aug 07;9(8):e104099 - PubMed
  14. Am J Surg. 1999 Jan;177(1):55-60 - PubMed
  15. Science. 2006 Sep 29;313(5795):1960-4 - PubMed
  16. Oncoimmunology. 2014 Jan 10;3:e27668 - PubMed
  17. Hum Pathol. 2003 Jun;34(6):605-9 - PubMed
  18. Mol Ther. 2011 Sep;19(9):1737-46 - PubMed
  19. Blood. 2012 Apr 12;119(15):3383-93 - PubMed
  20. J Clin Invest. 2014 Nov;124(11):4843-56 - PubMed
  21. Cancer Res. 2013 Dec 1;73(23):6900-12 - PubMed
  22. Cancer Immunol Immunother. 2015 Mar;64(3):271-4 - PubMed
  23. Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 - PubMed
  24. Gynecol Oncol. 2008 Feb;108(2):415-20 - PubMed
  25. Nat Rev Microbiol. 2010 Jan;8(1):62-73 - PubMed

Publication Types